Since October 2024, technology for all people living with type 1 diabetes (T1) has been fully funded. In Waikato, 66 per cent of people with T1 are now using Automated Insulin Delivery (AID), also known as insulin pump therapy.
If you have patients with T1 in your practice who are not currently using an insulin pump, we encourage you to discuss the benefits of AID with them and refer them to the Regional Diabetes Service via BPAC for assessment and support with transitioning. Evidence shows that AID can significantly improve quality of life and glycaemic control, without increasing hypoglycaemia, helping to reduce the risk of long-term diabetes-related complications.
For prescribing support, please refer to the T1 consumables prescriber guide for primary care. If you have any questions, contact Kathy Knight, Waikato Clinical Diabetes Specialist.
Kathy joined Pinnacle earlier this month as clinical diabetes specialist for Waikato, replacing the role previously held by Anne Waterman.
Read moreFrom 1 December 2025, Pharmac will remove Special Authority renewal requirements for several treatments, including insulin pump consumables, continuous glucose monitors, LAMA/LABA inhalers, epoetin alfa, budesonide capsules, and febuxostat.
Read moreFunding for patients who require a follow-up appointment following HbA1c retest by Awanui Labs.
This funding ends on 28 February 2026
A guide for clinical management of type 2 diabetes, to support nurses at all levels to develop their knowledge and clinical reasoning in diabetes care.